No Prescription |
 |
 | ||
|
URIMAX Flomax MR |
|
| ||
No Prescription » Prescription Drugs 16 » URIMAX Flomax MR Tamsulosin is used for: Treatment of enlargement of the prostate gland in men. This condition is known as benign prostatic hyperplasia (BPH). Tamsulosin (tam-SOO-loh-sin) is used to treat the signs and symptoms of benign enlargement of the prostate (benign prostatic hyperplasia or BPH). Benign enlargement of the prostate is a problem that can occur in men as they get older. The prostate gland is located below the bladder. As the prostate gland enlarges certain muscles in the gland may become tight and get in the way of the tube that drains urine from the bladder. This can cause problems in urinating such as a need to urinate often a weak stream when urinating or a feeling of not being able to empty the bladder completely.Tamsulosin helps relax the muscles in the prostate and the opening of the bladder. This may help increase the flow of urine and/or decrease the symptoms. However tamsulosin will not shrink the prostate. The prostate may continue to get larger. This may cause the symptoms to become worse over time. Therefore even though tamsulosin may lessen the problems caused by enlarged prostate now surgery still may be needed in the future. Buy URIMAX Flomax MR and other Prescription Drugs 16 products online at Medstore. Buy Online at Medstore - Click Here!
About URIMAX Flomax MR: Product Type: Prescription Drugs 16 URIMAX ( Flomax MR Generic Tamsulosin ) URIMAX (Flomax MR Generic Tamsulosin) Flomax MR Generic Tamsulosin 400mcg Flomax MR Generic Tamsulosin URIMAX
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
